Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era

2 weeks ago 12

Vandita Jadeja

Mon, May 4, 2026 astatine 9:09 AM CDT 4 min read

Quick Read

Pfizer (PFE) posted Q4 adjusted EPS of $0.66 beating the $0.57 statement connected $17.56B successful gross portion its non-COVID portfolio grew 9% operationally, led by Abrysvo (+136%) and Lorbrena (+45%), positive a $7.0B Metsera acquisition for obesity drugs with 20 planned pivotal trials successful 2026.
Moderna (MRNA) reported Q4 gross of $678M (down 29% YoY) and a nonaccomplishment per stock of $2.11 (beating the $2.62 estimate) portion cutting astir $2.2B successful yearly operating expenses and expanding planetary manufacturing crossed the UK, Australia, and Canada.
Pfizer is pivoting toward a diversified pharma strategy anchored successful obesity and oncology with near-term catalysts, portion Moderna is betting everything connected mRNA level breadth done oncology partnerships and pipeline enlargement aft its COVID gross cliff.
The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Moderna wasn't 1 of them. Get them present FREE.

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) conscionable closed the books connected Q4 2025, and the opposition is striking. Pfizer leaned connected a diversified non-COVID portfolio and a caller propulsion into obesity drugs.

Moderna leaned connected outgo cuts and planetary enlargement to soften a steep COVID gross cliff. Two precise antithetic pharma stories, some shaped by beingness aft the pandemic windfall.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Moderna wasn't 1 of them. Get them present FREE.

Diversified Drugmaker Beats. mRNA Pure-Play Survives.

Pfizer posted adjusted EPS of $0.66 against a $0.57 statement connected $17.56 cardinal successful revenue, with the apical enactment dipping conscionable 1.2% twelvemonth implicit year. The non-COVID publication did the dense lifting, increasing 9% operationally.

Standouts included Abrysvo astatine +136% and Lorbrena astatine +45%. The bruise: a $4.4 cardinal non-cash impairment tied to pipeline revisions dragged the GAAP enactment into a $1.65 cardinal nett loss. Ugly optics, but mostly accounting noise.

Moderna told a leaner story. Revenue landed astatine $678 million, down 29.08% twelvemonth implicit year, portion the nonaccomplishment per stock of $2.11 inactive bushed the $2.62 estimate.

CEO Stéphane Bancel pointed to "approximately $2.2 billion" successful yearly operating disbursal reductions, calling retired 3 caller planetary manufacturing sites successful the UK, Australia, and Canada. The merchandise communicative is thin: Spikevax, mNEXSPIKE, and mRESVIA. The pipeline communicative is wide.

An infographic titled 'Pfizer vs. Moderna: Post-Pandemic Pivot' connected a acheronian inheritance with greenish and bluish accents. It features a graphic of 2 diverging roads astatine the top. The infographic is divided into six sections: 1. Diversification vs. Focus, outlining Pfizer arsenic a 'Diversified Giant' and Moderna arsenic 'mRNA Pure-Play'. 2. Q4 2025 Earnings Snapshot, detailing adjusted EPS, revenue, non-COVID revenue, standouts, and nett nonaccomplishment for Pfizer; and EPS, revenue, operating expenses, merchandise portfolio, and planetary enlargement for Moderna. 3. Strategic Bets, listing absorption areas, cardinal moves/data, and 2026 plans for some companies. 4. Financial Comparison Table, showing Market Cap, Forward P/E, Dividend Yield, 1-Year Return, and Core Bet for Pfizer (PFE) and Moderna (MRNA). 5. Future Catalysts (2026), with gross guidance, adjusted EPS guidance, exclusivity impact, and cardinal trials for Pfizer; and gross guidance, currency projection, recognition installation draw, and cardinal readouts for Moderna. 6. Investment Thesis, describing Pfizer arsenic 'Steady Hands & Income' and Moderna arsenic 'High-Risk, High-Reward'. A root enactment 'Vetted Market Data, SEC Filings, Earnings Reports. Data arsenic of May 1, 2026' is astatine the bottom.

Obesity Bets vs Oncology mRNA

Pfizer's strategical pivot is unmistakable. Albert Bourla closed the $7 cardinal Metsera woody for ultra-long-acting GLP-1 obesity assets and is readying 10 pivotal proceedings starts successful 2026 from that level alone. He framed 2026 arsenic "an important twelvemonth affluent successful cardinal catalysts" with astir 20 pivotal survey starts.

Read Entire Article